Evidence map›Paper›PMID 41858082›Full record

Trial reportJournal of pediatric gastroenterology and nutrition2026

Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.

Danielle Wendel, Paul W Wales, Samuel Kocoshis, Robert Venick, Beth Carter, Valeria Cohran, Cheney Matthews, Bram P Raphael, Ian Robinson, Susan Hill

2 registry-linked trialsAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02949362 phase3completednot on this map

A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003

TypeinterventionalSponsorShireRan2016 to 2020Enrolled29ConditionsShort Bowel SyndromeArmsTeduglutide, SOC
NCT02954458 phase3completednot on this map

A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301

TypeinterventionalSponsorShireRan2017 to 2020Enrolled61ConditionsShort Bowel SyndromeArmsTED, SOC, Syringe, Needle
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Danielle WendelDivision of Gastroenterology and Hepatology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-5140-2956
Paul W WalesDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
Samuel KocoshisDivision of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Robert VenickDivision of Gastroenterology, Hepatology, and Nutrition, UCLA Mattel Children's Hospital, Los Angeles, California, USA.
Beth CarterChildren's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Valeria CohranDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
Cheney MatthewsTakeda Pharmaceuticals, U.S.A., Inc., Cambridge, Massachusetts, USA.
Bram P RaphaelTakeda Pharmaceuticals, U.S.A., Inc., Cambridge, Massachusetts, USA.
Ian RobinsonTakeda Pharmaceuticals, U.S.A., Inc., Cambridge, Massachusetts, USA.
Susan HillDepartment of Paediatric Gastroenterology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Funding

a Takeda companyClinical trials NCT02949362 and NCT02954458 were funded by Shire Human Genetic Therapies, Inc.Takeda Pharmaceuticals U.S.A., Inc.this post hoc analysis study was funded by Takeda Pharmaceuticals U.S.A., Inc.
6 · The paper itself

Abstract

objectivesThe complex care needs of pediatric patients with short bowel syndrome-associated intestinal failure (SBS-IF) can negatively impact the health-related quality of life (HRQoL) of patients and their caregivers. We assessed the impact of teduglutide on HRQoL of pediatric patients with SBS-IF.

methodsTwo long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module. Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study. We assessed changes in HRQoL over time, as well as the impact of attaining enteral autonomy on HRQoL and predictors of change in HRQoL.

resultsIn pediatric patients with SBS-IF receiving teduglutide (n = 69), the total mean (standard deviation) patient-reported PedsQL score was 75.0 (16.2). Higher mean number of stools per day at LTE study baseline (p = 0.03) predicted increased patient-reported HRQoL. Longer teduglutide exposure (p = 0.047), increasing length of remnant small intestine (p = 0.034), and older age (p = 0.026) predicted higher caregiver-proxy-reported HRQoL. Mean PedsQL scores remained stable over 96 weeks regardless of patients achieving enteral autonomy.

conclusionsHRQoL of pediatric patients with SBS-IF treated with teduglutide was generally stable over 96 weeks. Predictors of improved HRQoL included higher baseline stool number, longer teduglutide treatment duration, greater length of small intestine, and older age. To better understand these observations, future studies should assess HRQoL before initiation of treatment. CLINICAL

trial registrationClinical trials NCT02949362 and NCT02954458.

Indexed as

Gastrointestinal AgentsIntestinal FailurePeptidesQuality of LifeShort Bowel SyndromeAdolescentChildChild, PreschoolFemaleHumansMaleTreatment OutcomeGastrointestinal AgentsPeptidesteduglutidegastroenterologyglucagon‐like peptide‐2outcomes research/quality

Identifiers

PMID41858082
PMCPMC13342760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.